Get the Stockscreener App
0.7682
0.81%
-0.0063
Century Therapeutics Inc stock is traded at $0.7682, with a volume of 477.45K.
It is down -0.81% in the last 24 hours and down -15.52% over the past month.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
See More
Previous Close:
$0.7745
Open:
$0.7938
24h Volume:
477.45K
Relative Volume:
0.82
Market Cap:
$65.32M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.3355
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+5.13%
1M Performance:
-15.52%
6M Performance:
-52.29%
1Y Performance:
-83.66%
1-Day Range:
$0.751
$0.822
1-Week Range:
$0.705
$0.822
52-Week Range:
$0.681
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.7682 | 65.32M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.11 | 118.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.00 | 74.34B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
639.00 | 38.83B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.00 | 32.36B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.75 | 29.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Leerink Partnrs Has Strong Forecast for IPSC FY2024 Earnings - Defense World
Brokers Offer Predictions for IPSC FY2029 Earnings - Defense World
FY2029 Earnings Estimate for IPSC Issued By Leerink Partnrs - MarketBeat
Layoff Tracker: Q32, Inventiva, Third Harmonic Cut Staff - BioSpace
Ratios Reveal: Breaking Down Century Therapeutics Inc (IPSC)’s Financial Health - The Dwinnex
Quarterly Snapshot: Quick and Current Ratios for Janux Therapeutics Inc (JANX) - The Dwinnex
Analyzing Telephone And Data Systems, Inc (TDS) After Recent Trading Activity - Knox Daily
Balance Sheet Insights: BioXcel Therapeutics Inc (BTAI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Century Therapeutics COO Farid Adrienne sells $822 in stock - MSN
Century Therapeutics SVP sells shares worth $273 to cover taxes - MSN
Century Therapeutics COO Farid Adrienne sells $822 in stock By Investing.com - Investing.com Canada
Century Therapeutics SVP sells shares worth $273 to cover taxes By Investing.com - Investing.com Canada
Financial Metrics Exploration: Understanding Century Therapeutics Inc (IPSC) Through Ratios - The Dwinnex
JPMorgan Chase & Co. Has $123,000 Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Brokerages - Defense World
Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MyChesCo
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from Guggenheim - MarketBeat
HC Wainwright Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - MarketBeat
Century Therapeutics launches cell therapy trial for autoimmune diseases - MSN
4 Analysts Have This To Say About Century Therapeutics - Benzinga
Century Therapeutics Announces Investigator-Initiated Phase - GlobeNewswire
Century Therapeutics Pioneers First iPSC-Derived NK Cell Therapy Trial for Autoimmune Diseases - StockTitan
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 14.0% - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in December - Defense World
Jane Street Group LLC Sells 62,588 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Boosts Stake in Costamare Inc. (NYSE:CMRE) - Defense World
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MyChesCo
Century Therapeutics Unveils Advances in Cell Therapies - TipRanks
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Purchases 32,614 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Purchased by State Street Corp - Defense World
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Declines By 5.6% - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper Sandler - Defense World
Piper Sandler supports Century shares with Overweight rating as CAR-iNK study progresses - Investing.com UK
Century Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Nigeria
Charles Schwab Investment Management Inc. Sells 43,049 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):